LATEST NEWS
FDA approvals, safety reviews, recalls and what new medications mean in practice. Our coverage explains the evidence behind each decision and the questions worth asking a doctor or pharmacist.
Compounded Drugs
The federal government has moved to make some compounded peptide products more available even as FDA staff have warned the evidence for safety and effectiveness is thin.
Read article →
FDA Alerts
The FDA says certain Medline electric beds and accessories can overheat and catch fire. The agency cites two deaths, 16 serious injuries, and updated use instructions.
Read article →
Baby Nutrition
Federal regulators have proposed changes to long-standing infant formula nutrition standards, including updated targets for several nutrients and a fresh review of how formulas are labeled.
Read article →
Brain Health
A new randomized trial found high-dose DHA changed a brain-fluid marker but did not improve cognition or brain structure over two years, adding to doubts about fish oil supplements for dementia prevention.
Read article →
Cancer Care
A Washington Post report describes how some U.S. cancer patients and clinicians are turning to overseas sources when key medicines run short. The broader pattern reflects a stubborn reality: shortages can delay treatment, force…
Read article →Alzheimer
A clear guide to Alzheimer's medication: anti-amyloid infusions, cholinesterase inhibitors, memantine and drugs for sleep or agitation, plus their side effects.
Read article →
Consumer Health
Bemotrizinol is the first new U.S. sunscreen active ingredient in more than two decades, arriving as skin-cancer prevention remains a public health priority.
Read article →
Diabetes Care
Medicare’s open enrollment season is under way, and several policy changes scheduled for 2027 could affect drug costs, plan choices and access to widely used diabetes and weight-loss medicines.
Read article →
Artificial Intelligence
The FDA’s new fiscal 2027 guidance list shows that artificial intelligence will remain a major focus, with planned documents on AI-enabled device software, generative AI, and related evidence standards.
Read article →
Compounding Pharmacies
Federal advisers have opened the door to temporary access for several unapproved peptide products, even as FDA warnings continue to stress that compounded versions are not reviewed for safety, effectiveness or quality.
Read article →
Abortion Pill
The FDA says its ongoing safety review of mifepristone will continue into next year, keeping one of the nation’s most closely watched drug-policy fights in motion.
Read article →
Family Caregiving
AARP’s latest caregiving guidance highlights why medication lists in long-term care need regular review—especially for drugs linked to confusion, falls, and other side effects.
Read article →